SUMMARY The finding of raised growth hormone concentrations in patients with secondary malignancy in the liver is reported. These concentrations were significantly higher than those found in patients with primary malignancy only or in those with non-hepatic secondaries.
In 19791 we reported raised growth hormone concentrations in six cases of carcinoma of the bronchus with secondary deposits in the liver. A limited investigation of a small number of cases of other carcinomata, at that time, did not reveal any high growth hormone values although a limited rise occurred postoperatively both in some of these carcinoma patients and in patients suffering from non-malignant conditions.
In view of the fact that these findings might have some clinical value, a further study has been carried out to include a wider range of malignancy.
Material and methods
Growth hormone was estimated by radioimmunoassay using the Phadebas hGH Prist Kit. By this method our normal adult basal range is <1-0-5*0 ,ug/l (<2.0-10-0 mU/l). This is a double antibody technique, a method which increases the specificity and the second antibody is highly specific for growth hormone. It has been extensively tested and there is no cross reactivity with other human pituitary hormones. There is a well known cross reactivity with human placental lactogen which in a concentration of 16 000 ,ug/l would alter the growth hormone concentration by 3-5 ug/l (7-0 mU/l). This was not relevant to the patients studied.
Serum samples were taken under basal conditions, before 10.00 hrs from a total of 169 cases of malignancy. The carcinoma cases were 74 bronchus, 28 (Figure) . Each group shows a wide scatter and the small number could influence statistical analysis, nevertheless it will be seen that the growth hormone concentration in each type of malignancy and in each subdivision are comparable. The concentrations are higher in the group with liver secondaries and there is also some increase in the group with non-hepatic secondaries. From the Figure it will be seen that the distribution is non-Gaussian and using Hill's method applied to Fisher's exact test there is no statistical difference between the primary tumour groups and those with non-hepatic secondaries (p = 0.2137) but there is a highly significant difference both between the primary groups and the liver secondaries groups (p = 0.0000002) and also between those with liver secondaries and those with secondaries elsewhere (p = 0.0003).
Discussion
The high growth hormone concentrations found in patients with secondary carcinoma of the liver are not, as was formerly thought, a specific feature of carcinoma of the bronchus. Ectopic hormone production by non-endocrine tumours has been recognised with increasing frequency. Amongst these car- 
